Literature DB >> 10975307

Treatment of FSGS with plasma exchange and immunadsorption.

D Franke1, M Zimmering, N Wolfish, J H Ehrich, G Filler.   

Abstract

In primary focal and segmental glomerulosclerosis (FSGS) renal prognosis is poor if no remission of proteinuria can be achieved with treatment. Currently, most children with FSGS are treated with cyclosporine and steroids after establishing steroid resistance, and approximately 60% of patients benefit from this therapy. For the remaining 40%, no generally approved therapeutic recommendations exist for children. We treated nine children with cyclosporine-resistant primary FSGS with plasma exchange (PE), two with relapsing FSGS after renal transplantation and seven with FSGS in their native kidneys. Three patients did not respond to PE, but five came into complete remission and one patient achieved partial remission. Three patients relapsed between 6 weeks and 2 years following cessation of PE, and were subsequently treated with plasma immunadsorption (PIA), which also reliably reduced proteinuria. The patients without response to PE tended to have a longer duration of the disease. We conclude that PE and PIA are a useful option for treatment of steroid- and cyclosporine-resistant FSGS, particularly if applied early in the course of the disease. Although more demanding on supportive resources, PIA seems preferable to PE, since there is no necessity for additional albumin or fresh-frozen plasma, as with PE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975307     DOI: 10.1007/pl00013420

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  6 in total

Review 1.  Therapeutic apheresis.

Authors:  J P Isbister
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

Review 2.  Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.

Authors:  Koichi Kamei; Kenji Ishikura; Mayumi Sako; Shuichi Ito; Kandai Nozu; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2018-12-18       Impact factor: 3.714

Review 3.  The management of idiopathic nephrotic syndrome in children.

Authors:  Elisabeth Hodson
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Authors:  Kerstin Benz; Jörg Dötsch; Wolfgang Rascher; Daniel Stachel
Journal:  Pediatr Nephrol       Date:  2004-04-08       Impact factor: 3.714

5.  Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome.

Authors:  Kim Loeffler; Manjula Gowrishankar; Verna Yiu
Journal:  Pediatr Nephrol       Date:  2004-02-03       Impact factor: 3.714

6.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.

Authors:  Kenji Ishikura; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Yoshitsugu Kaku; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.617

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.